<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636543</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/32</org_study_id>
    <nct_id>NCT02636543</nct_id>
  </id_info>
  <brief_title>Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments</brief_title>
  <acronym>LIPEG</acronym>
  <official_title>Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The decree of June 20th 2013 (n° 2013-527) suggests a protocol regarding the transmission of&#xD;
      information to the relatives after genetic diagnosis of a serious condition. This decree&#xD;
      includes a specific model of letter that can be sent to relatives by genetic professionals.&#xD;
      We evaluated the understanding and feelings after the reading of the decree's letter (letter&#xD;
      A) on patients and the public. A focus group drafted a new version of the letter (letter B)&#xD;
      through these observations. The two letter models (A vs B) are compared in terms of impact&#xD;
      through precise items (understanding and feelings) on three populations: patients, public and&#xD;
      genetic professionals. Assumption is made that the letter B will be preferred to the letter&#xD;
      A. Overall, we aim at giving a letter formulation accommodating as many people as possible to&#xD;
      standardize practices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recent publication of the decree of June 20th 2013 (n° 2013-527) suggests a protocol&#xD;
      regarding the transmission of information of the relatives after genetic diagnosis of a&#xD;
      serious condition allowing preventative or care measures. In the case a mutation career&#xD;
      refuses to directly inform other members of his family, option is to call on services of a&#xD;
      genetic professional for the transmission of its family information. This decree includes a&#xD;
      specific model of letter that can be sent to relatives by genetic professionals.&#xD;
&#xD;
      The main objective of the present study is the standardization of the procedure concerning&#xD;
      the information to relatives by all genetic professionals. It would allow the same format of&#xD;
      information in all families involved.&#xD;
&#xD;
      The first part (study 1a) evaluated the understanding and feelings after the reading of the&#xD;
      decree's letter (letter A) on patients and the public, through the use of an individual and&#xD;
      oral questionnaire. Interviews with the patients, public, genetic professionals and people&#xD;
      who have received this letter completed the study 1a (study 1b). A focus group (accounting&#xD;
      different genetic professionals and patient associations) composed a new version of letter&#xD;
      (letter B) through these observations (study 1c).&#xD;
&#xD;
      The second part will compare the two letters model (A vs B) impact through precise items on&#xD;
      three populations: patients, public and genetic professionals. This study will allow to:&#xD;
&#xD;
        -  Evaluate how the letter composed by the focus group (letter A) is understood and&#xD;
           perceived by the patients and the public with the same methodology as study 1a (study&#xD;
           2a) ;&#xD;
&#xD;
        -  Compare the two letters model (A vs B) to describing the preference of patients, public&#xD;
           and genetic professionals (study 2b).&#xD;
&#xD;
      The expected results would help us to choose the letter accommodating as many people as&#xD;
      possible to standardize practices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score of understanding questionnaire after reading letter B.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of persons who prefer the letter B.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">325</enrollment>
  <condition>Transmission of Information to the Relatives After Genetic Diagnosis</condition>
  <arm_group>
    <arm_group_label>Group 2a-patient</arm_group_label>
    <description>75 patients who attended a genetic counselling consultation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a-public</arm_group_label>
    <description>75 persons belonging to general population.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b-patient</arm_group_label>
    <description>75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b-public</arm_group_label>
    <description>75 persons belonging to general population (those persons are different than patients from group 2a).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b-professional</arm_group_label>
    <description>75 genetic professionals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire after the reading of letter B.</intervention_name>
    <description>Oral questionnaire after the reading of letter B.</description>
    <arm_group_label>Group 2a-patient</arm_group_label>
    <arm_group_label>Group 2a-public</arm_group_label>
    <arm_group_label>Group 2b-patient</arm_group_label>
    <arm_group_label>Group 2b-professional</arm_group_label>
    <arm_group_label>Group 2b-public</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire after the reading of letters A and B</intervention_name>
    <description>Oral questionnaire after the reading of letters A and B during individual interview.</description>
    <arm_group_label>Group 2b-patient</arm_group_label>
    <arm_group_label>Group 2b-professional</arm_group_label>
    <arm_group_label>Group 2b-public</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Group 2a-patient: 75 patients who attended a genetic counselling consultation.&#xD;
&#xD;
          -  Group 2a-public: 75 persons belonging to the general population who never attended&#xD;
             genetic counselling consultation.&#xD;
&#xD;
          -  Group 2b-patient: 75 patients who attended a genetic counselling consultation.&#xD;
&#xD;
          -  Group 2b-public: 75 persons belonging to general population who never attendeda&#xD;
             genetic counselling consultation. These persons are different than persons from group&#xD;
             2a-person.&#xD;
&#xD;
          -  Group 2b-professionnal: 75 genetic professionals (geneticist and genetic counsellor).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old and above&#xD;
&#xD;
          -  French native speaker&#xD;
&#xD;
          -  informed person&#xD;
&#xD;
          -  person whose non-opposition has been received&#xD;
&#xD;
          -  public: person who never attended a genetic counselling consultation&#xD;
&#xD;
          -  professional: geneticist and genetic counsellors working in France&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  study 2a : person who took part of study 2b&#xD;
&#xD;
          -  study 2b : person who took part of study 2a&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécile ZORDAN, Ms</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Aquitaine</state>
        <zip>67080</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital SUD</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genetic diagnosis</keyword>
  <keyword>information</keyword>
  <keyword>letter model</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

